KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 20925 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Laparoscopic vs Open Distal Gastrectomy With D2 Lymphadenectomy for Clinical T4a Gastric Cancer: The UMC-UPPERGI-01 Randomized Clinical Trial. PMID 41222957 · JAMA Surg · 2026-Jan-01 The record is a randomized trial in oncology with original results, but it is excluded because it does not meet the required Phase (likely Phase II, not explicitly Phase III/IIIb or Phase II/III), does not have a time-to-event efficacy endpoint (focus is on short-term surgical outcomes), and does not involve a drug-containing intervention (surgical procedures only).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Atorvastatin and Aortic Stiffness During Anthracycline-Based Chemotherapy: A Secondary Analysis of a Randomized Clinical Trial. PMID 41205202 · JAMA Cardiol · 2026-Jan-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Efficacy of Acoramidis in Wild-Type and Variant Transthyretin Amyloid Cardiomyopathy: Results From ATTRibute-CM and Its Open-Label Extension. PMID 41205147 · JAMA Cardiol · 2026-Jan-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Effects of aprocitentan on prognostically relevant ambulatory blood pressure-derived variables in resistant hypertension. PMID 41195725 · J Hypertens · 2026-Jan-01 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Novel niclosamide stearate prodrug therapeutic shows potential efficacy against naturally occurring canine osteosarcoma in a clinical feasibility study. PMID 41145069 · Am J Vet Res · 2026-Jan-01 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。
H S B
严格 v3 独有 eligibleexplicit_phase3_randomized needs_review 0 Figure · 0 Panel · risk not_assessed
Sacituzumab Tirumotecan in EGFR-TKI-Resistant, EGFR-Mutated Advanced NSCLC. PMID 41124220 · N Engl J Med · 2026-Jan-01 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Survival with Osimertinib plus Chemotherapy in EGFR-Mutated Advanced NSCLC. PMID 41104938 · N Engl J Med · 2026-Jan-01 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 0 Figure · 0 Panel · risk not_assessed
Early palliative care for patients with glioblastoma: A randomized phase III clinical trial (EPCOG). PMID 41071052 · Neuro Oncol · 2026-Jan-01 The trial is a randomized Phase III study in human glioblastoma (oncology) with a primary QoL endpoint and secondary palliative care outcomes. It is not a drug intervention trial (EIPC is a palliative care intervention, not a drug). The reported results include a survival difference (P=.018) but do not present it as a primary/key secondary time-to-event efficacy endpoint with Kaplan-Meier curves or hazard ratios. Therefore, it fails the drug intervention and time-to-event endpoint criteria.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Radioiodine Plus Low-Dose Lenvatinib in Radioiodine-Sensitive High-Volume Metastatic Differentiated Thyroid Cancer: A Pilot Study. PMID 41021893 · Clin Nucl Med · 2026-Jan-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Long-Term Ozanimod Therapy in Patients With Moderately Active Ulcerative Colitis After Failure of 5-Aminosalicylic Acid. PMID 41003640 · Inflamm Bowel Dis · 2026-Jan-01 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Anti-TNF Therapies Promote a Proximal-to-Distal Healing Pattern in Moderate-to-Severe Ulcerative Colitis. PMID 40997114 · Inflamm Bowel Dis · 2026-Jan-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L B
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Effect of intraoperative low-dose esketamine on postoperative quality of recovery in patients undergoing laparotomy for gynecologic malignancy: a randomized controlled trial. PMID 40990647 · Int J Surg · 2026-Jan-01 While the study is a randomized, oncology drug trial with original results, it does not meet the required primary/key secondary time-to-event efficacy endpoint criterion (OS, PFS, DFS, EFS, RFS, TTP, or analysis via Kaplan-Meier/HR).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Juvenile Spondyloarthritis Disease Activity Index Validation in Enthesitis-Related Arthritis and Juvenile Psoriatic Arthritis in a Prospective Clinical Trial Setting. PMID 40953957 · J Rheumatol · 2026-Jan-01 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Impact of D3 lymph node dissection extent on postoperative bowel function and nutritional status in right-sided colon cancer: a prospective randomized controlled trial. PMID 40928287 · Int J Surg · 2026-Jan-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Effects of Resistance versus High-Intensity Interval Training on Myokines and Cancer Cell Suppression in Breast Cancer Survivors: A Randomized Trial. PMID 40903011 · Med Sci Sports Exerc · 2026-Jan-01 The study is a randomized trial in oncology but fails on multiple required criteria: no drug intervention, no specified definitive phase, and no time-to-event endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy and safety of SHR-1701 combined with chemoradiotherapy as neoadjuvant treatment for locally advanced rectal cancer. PMID 40876501 · Cancer Lett · 2026-Jan-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Self-Perceived Hearing Outcomes With Radiation and Cisplatin or Radiation and Cetuximab for Patients With Human Papilloma Virus (HPV)-Positive Oropharyngeal Cancer-Results From NRG Oncology RTOG 1016. PMID 40829719 · Int J Radiat Oncol Biol Phys · 2026-Jan-01 This is a secondary analysis of a Phase III randomized trial in oncology with a drug intervention, but it does not report a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS). The endpoint is a patient-reported outcome (hearing handicap).
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Impact of minimal residual disease on the outcome of hematopoietic stem cell transplantation for childhood acute lymphoblastic leukemia within the FORUM trial. PMID 40820816 · Haematologica · 2026-Jan-01 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 2 Figure · 16 Panel · risk unclear
A multicenter randomized controlled trial of intrapleural perfusion of methotrexate-loaded tumor cell-derived microparticles combined with systemic therapy for malignant pleural effusion. PMID 40818045 · Int J Cancer · 2026-Jan-01 The study is a randomized, controlled, human oncology trial with a drug intervention and primary time-to-event endpoint (OS). However, it is not explicitly identified as a Phase III or Phase II/III trial. The abstract and metadata do not specify the trial phase. Per the adjudication rules, the phase must be explicitly established to be eligible; it cannot be inferred. Therefore, it does not meet the 'phase3_or_definitive' criterion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
HYPofractionated Adjuvant RadioTherapy in 1 Versus 2 Weeks in High-Risk Patients With Breast Cancer (HYPART): Acute Toxicity Results. PMID 40780546 · Int J Radiat Oncol Biol Phys · 2026-Jan-01 The report is an original result from a randomized Phase III oncology trial in humans, but the intervention is radiation therapy without a drug component, and the primary endpoint reported is acute toxicity, not a time-to-event efficacy outcome like OS, PFS, DFS, EFS, RFS, TTP, or its associated Kaplan-Meier/HR analysis.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Late Toxicities and Quality of Life After a Radiation Boost for Breast Ductal Carcinoma In Situ: Boost or No Boost in DCIS Randomized Trial. PMID 40752655 · Int J Radiat Oncol Biol Phys · 2026-Jan-01 The record is a Phase III randomized trial in oncology (breast DCIS) with a time-to-event primary endpoint (local recurrence-free survival). However, the intervention is radiation therapy (a non-drug modality). The current report is an original results paper, but it explicitly covers only secondary endpoints (toxicity, quality of life) because the primary endpoint has not been reached. It therefore does not meet the criterion of reporting the primary/key secondary time-to-event efficacy endpoint. The drug intervention criterion also fails.
H L S B
旧组与严格 v3 交集 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Randomized, double-blind phase III trial of a dexamethasone-free regimen for managing highly emetogenic chemotherapy-induced nausea and vomiting. PMID 40735921 · Int J Cancer · 2026-Jan-01 The trial is a randomized, phase III oncology study with drug interventions, but its primary endpoint is a categorical response rate (complete response), not a time-to-event endpoint such as OS, PFS, or DFS. There is no mention of Kaplan-Meier analysis or hazard ratios.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Pain relief by targeting nonrestorative sleep in fibromyalgia: a phase 3 randomized trial of bedtime sublingual cyclobenzaprine. PMID 40627411 · Pain Med · 2026-Jan-01 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Low-dose Radiation Therapy Concurrent With Atezolizumab and Chemotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer: 3-Year Follow-up of a Multicenter, Single-arm, Phase 2 Trial (MATCH). PMID 40609842 · Int J Radiat Oncol Biol Phys · 2026-Jan-01 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Comparative study of Chinese herbal enema combined with mesalazine vs mesalazine alone in the treatment of ulcerative colitis: A randomized controlled trial. PMID 40533886 · J Chin Med Assoc · 2026-Jan-01 The study is a randomized controlled trial with a drug intervention (mesalazine) and reports primary efficacy results. However, it is excluded because it is not an oncology study (focus on ulcerative colitis) and does not have a time-to-event efficacy endpoint (OS, PFS, DFS, etc.) as required.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Neoadjuvant Chemotherapy With Gemcitabine and S-1 Versus Upfront Surgery for Resectable Pancreatic Cancer: Results of the Randomized Phase II/III Prep-02/JSAP05 Trial. PMID 40235447 · Ann Surg · 2026-Jan-01 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
H L S B
旧组与严格 v3 交集 eligiblephase3_publication_type needs_review 1 Figure · 2 Panel · risk unclear
The relationship between mean arterial pressure and terlipressin in hepatorenal syndrome-acute kidney injury reversal: A post hoc analysis. PMID 40053863 · Hepatology · 2026-Jan-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Metformin modifies hormone changes associated with androgen deprivation therapy for prostate cancer. PMID 42395839 · Endocr Oncol · 2026-Jan The record describes a Phase III randomized controlled trial in oncology with a drug intervention and original results, but the primary endpoint is a change in biomarkers associated with metabolic syndrome, not a time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP). No Kaplan-Meier survival curves or hazard ratios are reported or implied.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A Prospective Study Comparing Treatment Outcomes of Brentuximab Vedotin Plus AVD versus ABVD in Egyptian Patients with Advanced Classical Hodgkin Lymphoma. PMID 42274064 · Gulf J Oncolog · 2026-Jan The record describes a randomized, prospective, open-label study comparing a drug-containing regimen (Brentuximab Vedotin + AVD) vs. ABVD in advanced Hodgkin lymphoma, with a primary time-to-event endpoint (PFS). It is an original report of results. However, the title, abstract, and metadata do not explicitly state the trial phase (e.g., Phase III). The deterministic review flagged 'phase3_evidence_unclear'. The inclusion criterion requires the phase to be explicitly established as Phase III/IIIb or Phase II/III, which is not present here. Therefore, is_eligible is set to false.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
[Breast cancer: an example of changing practices that take age-related factors into account. About the ASTER 70s study]. PMID 41729638 · Rev Prat · 2026-Jan The record describes a Phase III randomized trial in oncology (breast cancer) with a drug intervention (adjuvant chemotherapy) and is a primary result report. However, the abstract does not explicitly mention a primary/key secondary time-to-event efficacy endpoint such as OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR. The deterministic review correctly identified the absence of a time-to-event signal, making eligibility uncertain. Without explicit confirmation of a time-to-event endpoint, the record cannot be deemed eligible.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Hypofractionated split-course versus standard radiotherapy in frail older patients with head and neck squamous-cell carcinoma (ELAN-RT trial): a non-inferiority, multicentre, open-label, randomised controlled trial. PMID 41713468 · Lancet Healthy Longev · 2026-Jan The study is a randomized, open-label, non-inferiority trial in frail older patients with head and neck squamous-cell carcinoma. It reports a primary efficacy endpoint (6-month complete locoregional response rate) and a key secondary time-to-event endpoint (overall survival with HR). However, the intervention consists solely of two different radiotherapy fractionation schedules (standard vs. hypofractionated split-course). There is no drug-containing intervention (e.g., chemotherapy, targeted therapy, immunotherapy). Therefore, it does not meet the criterion of a drug-containing intervention required for this cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Zanubrutinib versus ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: health-related quality of life in a subgroup of Chinese patients in the ALPINE trial. PMID 41686056 · Curr Med Res Opin · 2026-Jan 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L B
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Reporting quality and risk of bias in randomized controlled trials of rotavirus vaccines. PMID 41660219 · Clin Exp Vaccine Res · 2026-Jan 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Overview of the Efficacy and Safety of Topical Hormonal Therapies for the Treatment of Acne Vulgaris: A Narrative Review. PMID 41648090 · J Clin Aesthet Dermatol · 2026-Jan 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H
仅历史库存 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Mirvetuximab soravtansine-Gynx (MIRV) for treating platinum-resistant recurrent ovarian cancer. PMID 41617329 · Taiwan J Obstet Gynecol · 2026-Jan 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Association between statin use and risk of incident cancer in healthy older adults: a target trial emulation using data from a multicentre, randomised trial of community-dwelling older adults in Australia and the USA. PMID 41583365 · EClinicalMedicine · 2026-Jan The record is an observational target trial emulation analyzing statin use as an exposure, not a randomized trial of a drug intervention. It does not meet the core criteria for being a randomized trial of a drug intervention in a defined phase.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Time-Dependent Comparative Effectiveness of First-Line Treatment for Metastatic Clear Cell Renal Cell Carcinoma: A Restricted Mean Survival Time-Based Network Meta-analysis. PMID 41575641 · Target Oncol · 2026-Jan 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
An Improved Bayesian Pick-the-Winner (IBPW) Design for Randomized Phase II Clinical Trials. PMID 41569686 · Stat Med · 2026-Jan 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Diagnostic and Therapeutic Potential of Substance P/NK1 Receptor in Primary Dysmenorrhea: A Pilot Study. PMID 41561887 · Health Sci Rep · 2026-Jan 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Real-world effectiveness of biologic therapies in severe asthma patients ineligible for phase 3 randomised controlled trials of biologics: an analysis from the UK Severe Asthma Registry. PMID 41561108 · ERJ Open Res · 2026-Jan 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Triplet regimens for frontline treatment of CLL-Great company or just a crowd? PMID 41560849 · Hemasphere · 2026-Jan 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
The evolving role of radiotherapy in advanced non-small cell lung cancer: beyond symptom control. PMID 41560507 · Ann Palliat Med · 2026-Jan 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Learning together to promote mental health and well-being in English secondary schools: LTMH study refinement and feasibility evaluation, a comprehensive synopsis. PMID 41556286 · Public Health Res (Southampt) · 2026-Jan 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Optimising the European Code Against Cancer, 5th edition, to increase awareness of avoidable cancer risks in all socioeconomic groups. PMID 41542812 · Mol Oncol · 2026-Jan The record is a randomized trial on cancer prevention awareness, but it does not meet key eligibility criteria: it lacks a drug intervention and does not report a time-to-event efficacy endpoint (e.g., OS, PFS, KM, HR).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Iptacopan in Patients With IgA Nephropathy From East Asia. PMID 41541777 · Kidney Int Rep · 2026-Jan 未发现恶性肿瘤人群证据。
H
仅历史库存 excludednon_oncology pending 0 Figure · 0 Panel · risk -
AI-Enhanced Versus Clinician-Guided Expressive Writing for Improving Psychological Well-Being in Cancer Survivors: A Randomized Controlled Trial. PMID 41539978 · Psychooncology · 2026-Jan The study is an oncology randomized trial with human participants and original results, but it fails two key eligibility criteria: it does not involve a drug-containing intervention (it is a psychological/behavioral intervention) and it does not have a primary or key secondary time-to-event efficacy endpoint (OS, PFS, DFS, etc.).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A randomized phase III trial of structured tumour response surveillance and shared decision-making for organ preservation in rectal cancer - PRODIGE 101-GRECCAR 20-EVAREC trial protocol. PMID 41536139 · Colorectal Dis · 2026-Jan 方案论文未报告临床试验结果。
H S B
严格 v3 独有 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Gemogenovatucel-T Advantage in Clonal Tumor Mutation Burden-High Ovarian Cancer. PMID 41533999 · JCO Precis Oncol · 2026-Jan 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Association Between the Angioedema Control Test and Attack Frequency in Hereditary Angioedema. PMID 41525239 · Clin Transl Allergy · 2026-Jan 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H
仅历史库存 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Phase II randomized study of first-line carboplatin and paclitaxel in combination with pembrolizumab, followed by maintenance pembrolizumab alone or with nesuparib, in mismatch-repair proficient, advanced or recurrent endometrial cancer (PENELOPE). PMID 41514313 · J Gynecol Oncol · 2026-Jan 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -